Background. Although females have a survival advantage in the general population, women undergoing dialysis have similar mortality to men. Because the reasons for this difference are unknown, we hypothesized that sex differences in cardiovascular disease (CVD) risk profile exist at dialysis initiation and that the association of such risk factors with mortality differs between sexes. Methods. This study was a prospective observational cohort study (NECOSAD) of incident dialysis patients with 5 years of follow-up where we calculated male:female odds ratios (OR) and relative risks of mortality (hazard ratio, HR) for the presence of CVD risk factors at the start of dialysis. We also examined the presence of interaction between sex and CVD risk factors in their association with mortality. Results. In 1577 patients (61% men, 60±15 years), men presented more CVD co-morbidity Conclusion. Despite a lower prevalence of CVD, women starting dialysis had the same mortality risk as men. The mortality risk was strikingly higher in diabetic women than diabetic men. This excess mortality may help explain why dialysis cancels out the female survival advantage. Our
Introduction
In the general population, women have a longer life expectancy than men [1] . This may partly be explained by a lower prevalence of cardiovascular risk factors and events in women, who have also been found to have a longer life expectancy in populations with manifest atherosclerosis [2] [3] [4] [5] . Possibly because of a faster progression to end-stage renal disease (ESRD) in men, the proportion of men initiating dialysis is higher than women [6] [7] [8] . However, unlike the general population, females on dialysis appear to lose the survival advantage observed elsewhere [9, 10] , bringing the mortality of women on dialysis to the same levels as men on dialysis. Interestingly, this survival cancellation is not restored after transplantation [11] . To our knowledge, the reasons for this finding have not been fully investigated. Understanding the reasons of the attenuation in the female survival advantage during dialysis may increase our understanding of the causes of the increased mortality risk in ESRD and could potentially influence therapy [12] .
ESRD is associated with a markedly increased mortality risk, cardiovascular disease (CVD) being the most common cause of death in this population [13] . We hypothesized that women with ESRD have a similar risk profile to men, thus explaining their relatively higher mortality upon dialysis initiation. Furthermore, we hypothesized that there may be sex differences in the impact of certain CVD risk factors on outcome. Therefore, our objective was to study the prevalence of CVD risk factors at the start of chronic dialysis treatment and to study whether their association with mortality is different in men and women starting dialysis. We did so in a large cohort of incident ESRD patients starting dialysis in the Netherlands.
Materials and methods

Subjects
End-stage renal disease patients of at least 18 years of age and starting with dialysis treatment as their first renal replacement therapy were eligible for inclusion in the NECOSAD Study. The Medical Ethical Committees of the participating dialysis centres approved the study, and all participants gave their written informed consent before inclusion. For the present analysis, all patients from whom information on CVD risk profile was available at 3 months after the start of dialysis were included (n = 1577).
Study design
NECOSAD is a multi-centre, prospective, observational cohort study that has been performed since 1997 in 38 dialysis centres in The Netherlands. Incident dialysis patients fulfilling inclusion criteria were enrolled in this study. Compared with the Dutch Renal Replacement Registry (ERA-EDTA Registry 2005 Annual Report. http://www.renine.nl/index.php? page=stt_2005/1, accessed 15/03/2008), the NECOSAD population was similar to the Dutch ESRD population with regard to age, sex, dialysis therapy, primary kidney disease and mortality. Three months after the start of dialysis was considered as the baseline of the present analyses. Dates and causes of mortality were immediately reported during follow-up. Survival time was defined as the number of days between 3 months after the start of the dialysis treatment (baseline) and the date of death, or the date of censoring due to loss to follow-up (kidney transplantation or transfer to a non-participating dialysis centre), the end of the follow-up on 1 January 2007 or at a maximum follow-up of 5 years.
Data collection
At inclusion, baseline demographic data and clinical data such as age, sex, body mass index (BMI), smoking habits, ethnicity, primary kidney disease and co-morbidity were recorded. Primary kidney diseases and causes of death were classified according to the coding system of the European Renal Association-European Dialysis and Transplantation Association [14] . The following codes were classified as death due to CVD: 11 (myocardial ischaemia and infarction), 12 (hyperkalaemia), 14 (other causes of cardiac failure), 15 (cardiac arrest, cause unknown), 16 (hypertensive cardiac failure), 17 (hypokalaemia), 18 (fluid overload), 22 (cerebrovascular accident), 26 (haemorrhage from ruptured vascular aneurysm), 29 (mesenteric infarction) and 0 (cause of death uncertain/not determined). All other codes were regarded as deaths of non-cardiovascular (non-CVD) origin. Routine measurements at 3 months after the start of dialysis included blood pressure, serum total cholesterol, plasma urea and plasma creatinine. In a 24-h urine sample at the same day, urea, creatinine and protein were assessed. Renal function was calculated from the mean of creatinine and urea clearance, adjusted for body surface area (mL/min/1.73 m 2 ). Clinical diagnoses of co-morbid conditions were reported by the patients' nephrologists at the time of inclusion and included diabetes mellitus (DM) and cardiovascular diseases. The co-morbidity index of Khan was calculated in which age and co-morbid conditions are combined into three risk groups classifying patients to have a low, medium or high mortality risk [15] . The presence of cardiovascular co-morbidity at baseline was defined as having one or more of the following clinical diagnoses: angina pectoris, previous myocardial infarction, congestive heart failure, previous cerebrovascular incident or overt peripheral vascular disease. The CVD risk profile of the patients included BMI, blood pressure, serum cholesterol concentrations, smoking habits and also pre-existing diagnoses of CVD and DM at the baseline of the study. BMI at baseline was calculated as the weight in kilograms divided by the height in square metres. . Systolic and diastolic blood pressures of the patients were calculated as the average of the pre-dialysis and post-dialysis blood pressure measurements of eight consecutive dialysis sessions. Hypertension was defined on the basis of current therapy guidelines as a systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg [16] . Hypercholesterolaemia was defined as having a total cholesterol concentration above 4.9 mmol/L. Smoking was scored as current, previous or non-smoker.
Statistical analysis
Mean values with standard deviations were calculated for continuous variables at baseline; categorical variables were expressed as proportions. Differences in variables between men and women were tested with Student's T-test or chi-square test where appropriate. We calculated male:female odds ratios associated with the presence of cardiovascular risk factors at baseline using logistic regression analysis. The observed cumulative survival for men and women was computed by the Kaplan-Meier method. With Cox regression analysis, we calculated the hazard ratio (HR, equivalent to relative risks of mortality) with 95% confidence intervals for men as compared with women. We examined the presence of interactions between sex and the cardiovascular risk factors with mortality. For the assessment of interaction of each specific risk factor, we created a new variable containing four categories: women without the risk factor, women with the risk factor, men without the risk factor and men with the risk factor. Hazard ratios with 95% confidence intervals were estimated for each category using women without risk factor as the reference category. We calculated the relative excess risk due to interaction (RERI) and the synergy index (S) as measures of additive interaction between sex and the risk factors in the association with mortality [17, 18] . Although it can be argued that all other risk factors are intermediate factors between sex and mortality, in a second step we also adjusted the analyses for age, initial treatment modality, primary kidney disease, co-morbidity, smoking, BMI, cholesterol, systolic and diastolic blood pressure and use of antihypertensive and lipid-lowering drugs to explore the influences of differences between men and women at baseline and estimate the hazard ratios if all other variables were equal. We used continuous variables for such adjustments whenever possible. We performed several sensitivity analyses, additionally adjusting for C-reactive protein (CRP) as a marker of inflammation and restricting the analyses once to patients with a BMI <25 kg/m 2 . All analyses were done on SPSS 14.0 for Windows (SPSS, Chicago, IL).
Results
Patient characteristics
Out of the 1940 ESRD patients starting dialysis, 1819 were still receiving dialysis after 3 months, the time point considered as the baseline of this study. In 102 of these patients, data on co-morbidity were missing, whereas in another 121, serum total cholesterol had not been determined. In the remaining 1596 patients, blood pressure had not been recorded in eight patients, BMI was unavailable in even patients, and information on smoking habits was not present in another four patients. Thus, full data on CVD risk profile was available in 1577 patients (958 men and 619 women), who were included in the present anaSex differences on diabetes and outcome 271 lysis. The baseline characteristics of the study population are shown in Table 1 ; 40% of the patients were overweight, with 10% considered obese; 23% had diabetes mellitus, and 36% had CVD at baseline. Men more often had renal vascular disease as primary kidney disease, and women more often started with haemodialysis (HD) treatment.
Male:female odds ratios for CVD risk profile at the start of dialysis Table 1 also lists the crude male:female odds ratios (ORs) for CVD risk factors. Men more often had CVD comorbidity and were more often smokers, whereas women more often suffered from DM, exhibiting lower diastolic blood pressure and higher serum cholesterol concentrations. Although an equal number of men and women had a BMI ≥25 kg/m 2 , more men were classified as overweight (33% vs 27% with a BMI between 25 and 30 kg/m 2 ), whereas more women were classified as obese (14% vs 7% with a BMI ≥30 kg/m 2 ).
Mortality risk associated with sex
In 5 years of follow-up after the start of dialysis, 593 patients died, of which 288 were due to CVD. There was no difference in cumulative mortality of male and female Interactions between sex and CVD risk profile in the association with mortality Table 2 shows the hazard ratios for men and women with or without specific CVD risk factors. The mortality risk associated to the presence of hypertension, overweight/ obesity or high cholesterol concentrations did not differ between men and women, neither in crude analysis nor after adjustment. In contrast, women with diabetes had a higher mortality risk than their male counterparts. Compared with women without diabetes, women with diabetes had a 3-fold higher mortality risk, whereas men with diabetes had a 2-fold higher mortality risk ( Table 2 ). The interaction measures RERI (−1.18, 95% CI: −0.37, −2.00) and S (0.47, 95% CI: 0.29, 0.75) both showed a supra-additive effect of sex and diabetes. Figure 1 shows the cumulative mortality of the dialysis patients during 5 years of follow-up by sex and diabetes. After adjustment 
Causes of death and mortality rates in men and women with ESRD
In the total study population, the mortality rates for allcause and CVD mortality were similar between men and women with ESRD. In order to further explore the observed interaction effect between sex and DM, we calculated mortality rates for all-cause and CVD mortality in men and women with and without pre-existing diabetes (Table 3) . Both all-cause and CVD mortality rates were higher in diabetic women than in diabetic men, but the proportion of deaths due to CVD was similar in both groups. When analysing individual causes of death, no striking difference or pattern was observed for diabetic men and women: The causes of death were known in 101 (out of 105) diabetic women and in 91 (out of 95) diabetic men. Fifty women vs 49 men died from CVD. The remaining non-CVD causes of death are distributed similarly between sexes (showing number of deaths for women vs men): haemorrhages, 0 vs 2; septicaemia, 9 vs 6; refusal of further treatment, 11 vs 8; termination of treatment for other reasons, 13 vs 9; malignant diseases, 2 vs 7; accident related to treatment, 0 vs 2; pulmonary bacterial infection, 2 vs 3; dementia, 1 vs 1; perforation of colon, 0 vs 2; haemorrhagic pericardititis, 0 vs 1; peritonitis, 2 vs 0; liver failure, 1 vs 1; cachexia, 3 vs 0; pulmonary embolus, 1 vs 0; and others, 6 vs 1. When stratified by dialysis modality, we found similar risk profiles in male and female peritoneal dialysis (PD) and HD patients with or without DM as in the total study population (data not shown). 
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Sensitivity analyses
Both non-smoking men and men without CVD seemed to have a lower mortality risk than their female counterparts. However, these effects disappeared when diabetic patients were excluded from the analyses, suggesting that such effects were attributable to the diabetic women of the reference groups. Specifically, in non-diabetic patients (n = 1222), the adjusted HRs were 1.12 (0.77, 1.63) for women with CVD, 0.83 (0.60, 1.13) for men without CVD and 1.31 (0.95, 1.81) for men with CVD, compared with women without CVD. Regarding smoking habits in non-diabetic patients, the adjusted HRs were 1.54 (1.08, 2.18) for smoking women, 0.99 (0.61, 1.61) for non-smoking men and 1.47 (1.08, 2.00) for smoking men, compared with nonsmoking women. Women with diabetes in our study population appeared to have a higher mean BMI than the men with diabetes (27.3 ± 5.6 vs 25.6 ± 4.2 kg/m 2 , P < 0.05). When restricting the analyses to patients with BMI <25 kg/m 2 (n = 943), compared with women without diabetes, the difference in mortality risk between men with diabetes (HR: 1.48, 95% CI: 0.89, 2.45) and women with diabetes (HR: 2.54, 95% CI: 1.55, 4.17) remained.
Finally, in a subgroup of patients where CRP measurements were available (n = 811), additional adjustment for CRP did not change our results: compared with women without diabetes, HRs were 2.29 (95% CI: 1.37, 3.83) for women with diabetes, 0.97 (95% CI: 0.70, 1.33) for men without diabetes and 1.30 (95% CI: 0.70, 1.33) for men with diabetes.
Discussion
In the present study, we investigated the sex-specific prevalence and interactions of baseline cardiovascular risk factors and diabetes mellitus in the association with 5-year mortality in 1577 ESRD patients starting dialysis treatment. Contrary to our hypothesis that an increased burden of CVD would explain an attenuation of the female survival advantage in ESRD, women had an almost 2-fold lower baseline prevalence of CVD co-morbidity than men but a higher proportion of diabetics. The mortality risk during the first 5 years of dialysis was similar in both sexes. Interestingly, this finding may partly be explained by an increased prevalence of diabetic women and an observed interaction between sex and diabetes, resulting in excess mortality in women with diabetes.
Whereas women usually show a survival advantage in the general population [1] , our finding of a similar mortality in men and women on a chronic dialysis treatment is in accordance with recent publications [9, 10, 19] . The authors speculate that differences in BMI or dialysis care could explain this finding. Accordingly, it has been reported, for instance, that women are at higher risk of short dialysis duration (<12 h/week) [20] or less likely to receive arteriovenous fistulas [21] . Our study expands these observations by also investigating the distribution of CVD risk factors between the sexes, observing that, comparable with the general population [3] , women in our study had a lower baseline prevalence of pre-existing CVD co-morbidity than did men. Also, and in agreement with previously published data [9, 10, 22] , women in our study were more likely to have diabetes than men. A previous report in type 2 diabetic ESRD patients aged ≥60 years showed a slightly increased mortality risk in women compared with men (HR: 1.19, 95% CI: 1.08-1.30) [10] . Our results extend these findings by showing that women with diabetes at the start of dialysis had an excess risk of mortality as compared with men with diabetes. This interaction effect may help to explain the attenuated survival advantage in ESRD women starting dialysis.
Our findings are in line with some reports in non-renal populations suggesting that diabetic women are at a higher cardiovascular mortality risk than diabetic men [23] [24] [25] . The exact mechanisms of this high risk in diabetic women remain unknown, but recent literature [23] has speculated that an increased prevalence of CVD risk factors in diabetic women combined with possible disparities in the level of medical care between the sexes may be important factors to explain their increased cardiovascular mortality. In our study of dialysis patients, however, the proportion of death from cardiovascular causes was not higher in diabetic women than in diabetic men, suggesting that these women were not more susceptible to CVD death. An alternative explanation may be that the survival differences arise due to differences in response to dialysis therapy, including a possible overestimation of HD adequacy in women [26] and a less effective PD in people with a small body size [27] . While our study was not designed to investigate these theories, it is noteworthy that adjustment for dialysis modality did not notably change the observed difference in mortality risks. Furthermore, as previous studies have suggested sex differences in the impact of inflammation [28] on survival and the symptoms associated to anorexia [29] , there may be yet other contributing factors. Additionally, body fat location may differ between men and women as well as be associated with different inflammatory and lipid profiles [30] . However, sensitivity analyses adjusting for BMI or CRP did not change our results. Finally, in early chronic kidney disease (CKD) stages, diabetes has been reported to be more prevalent in men, and risk factors such as age, BMI and plasma glucose contribute to exacerbate the male progression to ESRD [8] . Thus, the possibility of a higher mortality risk in pre-dialytic men, together with the documented faster CKD progression in men [6] [7] [8] , should as well be considered. A final hypothesis that cannot be excluded is that because diabetes is one of the main causes of CKD, an overrepresentation of diabetics exists and what we observe may be, in relative terms, a consequence of such natural selection. The strengths of the present study include the careful characterization of co-morbid conditions and CVD risk factors. The inability to differentiate between type 1 and type 2 diabetics may, however, weaken our results. Nonetheless, because of the relatively low prevalence of type 1 diabetes in ESRD patients [31] , we do not anticipate that excluding type 1 diabetics would have altered our results. The lack of data on markers of glycaemic control such as HbA1c is another limitation, as glycaemic control is known to be an important predictor of diabetic complications and survival of patients with ESRD and diabetes [32] . Since obesity has been linked to a poor glycaemic control [33] , the observation that the diabetic women had a higher mean BMI than the diabetic men may suggest that a worse glycaemic control in women could have contributed to their higher mortality risk. However, a difference in mortality between men and women with diabetes remained both after adjustment for BMI and when restricting the analysis to patients with BMI <25 kg/m 2 . In conclusion, the present study shows that, despite a 2-fold lower prevalence of CVD co-morbidity, women starting chronic dialysis have the same mortality risk as men. An observed increased prevalence of diabetes in women and an excess mortality in women with diabetes starting chronic dialysis treatment may contribute to explain this risk parity. Our study therefore identifies a high-risk group of patients that may warrant further investigation and benefit from intensified therapeutic care. Altogether, these results remark the critical importance of the treatment of co-morbidities in ESRD patients.
